{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:44:17Z","timestamp":1792485857781,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.molmed.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T18:55:51Z","timestamp":1750272951000},"page":"977-981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["IL-15 in CAR engineering: striking an efficacy\u2013safety balance"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2025.05.014_bb0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.05.014_bb0010","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","author":"Steffin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2025.05.014_bb0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.05.014_bb0020","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.molmed.2025.05.014_bb0025","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2025.05.014_bb0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.05.014_bb0035","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.05.014_bb0040","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2025.05.014_bb0045","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2025.05.014_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2025.05.014_bb0055","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","article-title":"Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.molmed.2025.05.014_bb0060","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41467-023-42619-2","article-title":"Unlocking the potential of allogeneic V\u03b42 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR\/IL-15 engineering","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2025.05.014_bb0065","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.molmed.2025.05.014_bb0070","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molmed.2025.05.014_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008572","article-title":"Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model","volume":"12","author":"S\u00e1nchez-Moreno","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491425001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:55:31Z","timestamp":1763765731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1471491425001376"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2025.05.014","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-15 in CAR engineering: striking an efficacy\u2013safety balance","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}